Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.32 +0.28 (+1.12%)
Official Closing Price Updated: 7:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Zoetis’s (NYSE:ZTS) Q1: Beats On Revenue, Full-Year Sales Guidance is Optimistic
Animal health company Zoetis (NYSE:ZTS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 1.4% year on year to $2.22 billion. The company’s full-year revenue guidance... 
Via StockStory
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new... 
Via Benzinga
Topics Government World Trade
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
Via The Motley Fool
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion. 
Via Benzinga
Kwizda Pharma Adopts CARA Life Sciences Platform for Rapid QMS Implementation with Minimal IT Resources
LONDON - April 30, 2025 - PRLog -- Kwizda Pharma, a division of Kwizda Holding GmbH and a leader in the Austrian healthcare market, has selected the CARA Life Sciences Platform from Generis, leading... 
Via PRLog
Topics Artificial Intelligence
Buy Pfizer Stock For A Rebound After Crushing Q1 EPS Expectations?
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 S&P 500 Stocks Worth Investigating and 1 to Avoid
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
Where Will Viking Therapeutics Be in 3 Years?
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years. 
Via The Motley Fool
Topics Bankruptcy
3 No-Brainer Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought in May
Three supercharged income stocks -- sporting an average yield of 8.63% -- are perfectly positioned to fatten investors' pocketbooks. 
Via The Motley Fool
Topics World Trade
1 Safe-and-Steady Stock to Target This Week and 2 to Be Wary Of
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
3 High-Yield Dividend Stocks That Could Rally Near 52-Week Lows
AES Corp., Pfizer, and LyondelBasell are examples of stocks offering a high-yield dividend today and potential upside in the latter half of 2025 
Via MarketBeat
Topics Economy Energy Government
US Stock Futures Rise As Meta, Microsoft Earnings Fuel Optimism: GDP Slump Linked To Tariff Anticipation, Not Recession, Says Analyst
U.S. stock futures rose early Thursday morning, following the robust earnings of two "Mag 7" companies after markets closed on Wednesday. 
Via Benzinga
Topics Economy
Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 3 Ultra-High-Yield Stocks.
There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are hiding in plain sight. 
Via The Motley Fool
Topics Bonds World Trade
Could Pfizer’s 7.1% Yield Be A Trap?
It’s easy to understand why income investors are interested in Pfizer. With a current yield of 7.1%, it’s one of the highest-yielding stocks in the S&P 500. Let’s dig into the dividend and see whether... 
Via Talk Markets
Topics Stocks
Pfizer CEO Albert Bourla Emphasizes National Security In US Drug Manufacturing
Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations and national security concerns. 
Via Benzinga
Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
Setting Goals: How to Navigate a Chronic Inflammatory Disease
(BPT) - Content sponsored and provided by Pfizer. Ashley partnered with Pfizer to share her experience living with moderate to severe rheumatoid arthritis (RA). 
Via Brandpoint
Stock Market Crash: 3 Absurdly Cheap Stocks to Load Up on for the Long Haul
Via The Motley Fool
Topics World Trade
This High-Yield Pharma Stock Looks Like an Incredible Bargain
Via The Motley Fool
Topics Intellectual Property
Pfizer's Dividend Yield Is 7.5%. Is It Still Safe?
Via The Motley Fool
Topics World Trade
US Stock Futures Fall After Tuesday Rally, But History Favors Bulls: Markets Rose 9 Of Last 10 Mays, Says Expert
U.S. stock futures are down Wednesday morning, despite major averages ending up on Tuesday, and the S&P 500 and Dow Jones notching their sixth-straight day in the green, the longest streak for the... 
Via Benzinga
Topics Stocks
Market Monitor April 30 ( Honeywell, Pfizer, UP - Spotify, Starbucks DOWN)
Wall Street Climbs as Confidence Dips and Rate Cut Hopes Rise 
Via Chartmill
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Via The Motley Fool
Dow Surges 300 Points Amid Trade Deal Hopes: Greed Index Remains In 'Fear' Zone
The CNN Money Fear and Greed index showed further easing in the overall fear level, while the index remained in the "Fear" zone on Tuesday. 
Via Benzinga
Topics Stocks
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain
Via The Motley Fool
Pfizer Could Make ‘Tremendous Investments’ In The US, But Here’s Why It’s Choosing Not To
Pfizer Inc. chief executive Albert Bourla says uncertainty related to higher tariffs on pharmaceutical imports under the Trump administration is discouraging the company from investing in the US. 
Via Talk Markets
Topics Government World Trade
Which S&P500 stocks are the most active on Tuesday?
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for... 
Via Chartmill
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market. 
Via Investor's Business Daily
Exploring the top movers within the S&P500 index during today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.